Vanda Pharmaceuticals (NASDAQ:VNDA) Posts Earnings Results, Beats Estimates By $0.31 EPS

Vanda Pharmaceuticals (NASDAQ:VNDA) issued its quarterly earnings results on Wednesday. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($0.68) by $0.31, FiscalAI reports. Vanda Pharmaceuticals had a negative return on equity of 49.81% and a negative net margin of 127.41%. The company had revenue of $69.81 million during the quarter, compared to the consensus estimate of $69.20 million.

Here are the key takeaways from Vanda Pharmaceuticals’ conference call:

• Third-quarter revenue rose 24% year over year to $69.8 million, driven by continued FANAPT growth, favorable HETLIOZ shipment timing, and early NEREUS sales. FANAPT prescriptions increased 25% year over year, while NEREUS prescriptions and unique prescribers each more than doubled sequentially.
• Vanda expects to launch BYSANTI in the fourth quarter of 2026, with commercial supplies nearly ready, and is preparing for a potential Quimilza launch in the first half of 2027 if the FDA approves its GPP application by the December 12 PDUFA date.
• Positive Phase III results could expand NEREUS into prevention of GLP-1-associated vomiting and HETLIOZ into delayed sleep-wake phase disorder. Management plans to discuss both programs with the FDA and pursue supplemental applications.
• Operating expenses declined 18% sequentially to $93.3 million as major development and launch-preparation activities concluded, and management expects further reductions in coming quarters.
• Vanda ended September with $140.5 million in cash, down $123.4 million from year-end 2025, and expects 2026 cash burn to exceed 2025 levels. HETLIOZ revenue remains vulnerable to generic competition and specialty-pharmacy inventory normalization, while NEREUS 2026 revenue is expected to remain below $10 million.

Vanda Pharmaceuticals Price Performance

VNDA traded up $0.10 during midday trading on Thursday, reaching $4.09. 1,360,366 shares of the company’s stock were exchanged, compared to its average volume of 1,489,500. The business has a 50-day simple moving average of $4.85 and a two-hundred day simple moving average of $6.25. Vanda Pharmaceuticals has a one year low of $3.79 and a one year high of $9.94. The firm has a market capitalization of $247.60 million, a price-to-earnings ratio of -0.88 and a beta of 0.69. The company has a quick ratio of 1.60, a current ratio of 1.61 and a debt-to-equity ratio of 0.01.

Vanda Pharmaceuticals News Roundup

Here are the key news stories impacting Vanda Pharmaceuticals this week:

• Positive Sentiment: Q3 revenue increased 24% year over year to approximately $69.8 million, driven by continued Fanapt growth and early sales from NEREUS. Revenue also rose 38% from the prior quarter. Vanda Pharmaceuticals Reports Third Quarter 2026 Financial Results
• Positive Sentiment: Vanda’s adjusted quarterly loss of $0.37 per share was narrower than consensus estimates of roughly $0.68-$0.72, while revenue modestly exceeded expectations. Vanda Q3 Earnings Report
• Positive Sentiment: Management reiterated expectations for more than $240 million in 2026 revenue, with the BYSANTI commercial launch expected in the fourth quarter. Vanda Revenue Target and BYSANTI Launch
• Positive Sentiment: Vanda announced positive Phase 3 NEREUS results for preventing vomiting associated with GLP-1 therapies. NEREUS is already commercially available for motion-induced vomiting, expanding the company’s potential growth opportunities. Positive NEREUS Phase 3 Results
• Neutral Sentiment: Quimilza’s biologics license application for generalized pustular psoriasis remains under FDA review, with a December 12, 2026 target action date. Approval could become a significant future catalyst, but the outcome remains uncertain.
• Negative Sentiment: Despite the revenue beat, Vanda remains unprofitable: operating expenses totaled $93.3 million, and the company reported a net loss of approximately $22.6 million, or $0.37 per share. Operating cash usage and a limited cash balance remain risks as the company funds launches and pipeline development. Vanda Third Quarter Financial Results

Wall Street Analyst Weigh In

VNDA has been the topic of several research analyst reports. Zacks Research cut Vanda Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Tuesday, October 6th. B. Riley Financial reaffirmed a “buy” rating and issued a $12.00 price target (down from $17.00) on shares of Vanda Pharmaceuticals in a research note on Monday, August 10th. Oppenheimer assumed coverage on Vanda Pharmaceuticals in a report on Wednesday, September 23rd. They issued an “outperform” rating and a $10.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price target on shares of Vanda Pharmaceuticals in a report on Monday, October 5th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a report on Thursday, October 15th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, Vanda Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $13.08.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system disorders and other conditions with significant unmet medical needs. Founded in 2003 and headquartered in Washington, DC, the company primarily serves patients and healthcare providers in the United States, with certain products and commercial rights extending to international markets.

Vanda’s marketed products include Hetlioz (tasimelteon), a treatment for Non-24-Hour Sleep-Wake Disorder in totally blind individuals and nighttime sleep disturbances associated with Smith-Magenis syndrome.